Metreleptin

Clinical data
Trade names	Myalept
Legal status	US: ℞-only
Identifiers
CAS Number	186018-45-1
DrugBank	DB09046 Y
UNII	TL60C27RLH Y
Synonyms	Mettreleptin; N-Methionylleptin; r-metHuLeptin
Chemical data
Formula	C714H1167N191O221S6
Molecular mass	16,156 g/mol

Metreleptin (Myalept) is a synthetic analog of the hormone leptin used to treat diabetes and various forms of dyslipidemia. It is has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.

Metreleptin is currently being investigated for the treatment of diabetes and/or hypertriglyceridemia, in patients with rare forms of lipodystrophy, syndromes characterized by abnormalities in adipose tissue distribution, and severe metabolic abnormalities.

In a three-year study of metreleptin in patients with lipodystrophy organized by the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health, metreleptin treatment was associated with a significant decrease in blood glucose (A1c decreased from 9.4% at baseline to 7.0% at study end) and triglyceride concentration (from 500 mg/dl at baseline to 200 mg/dl at study end). The Juvenile Diabetes Research Foundation has also partnered with Amylin Pharmaceuticals and researchers at the University of Texas Southwestern Medical Center to study whether metreleptin can be used to improve the treatment of type 1 diabetes.